Regulatory
The latest in regulatory for medical-aesthetics practice owners.
Regulatory
Allergan gets Health Canada nod for Boey, a fast-acting short-duration toxin
Boey (trenibotulinumtoxinE) is authorized in Canada for glabellar lines and works in hours instead of days, with effects lasting two to three weeks.
Regulatory
Indiana Tightens Medical Spa Regulations Under Public Law 136
New state law raises licensing and supervision requirements, affecting independent medspa operations and staffing models.
Regulatory
AbbVie Sues Galderma Over Patented Dermal Filler Syringe Designs
Patent litigation over syringe technology could affect filler supply and pricing dynamics.
Regulatory
Medicare Adds Botox to Price-Negotiation List — What Payers Negotiating Toxin Costs Means for Your Reimbursement
CMS includes Botox among 15 drugs eligible for Medicare price negotiation in 2026, signaling payer focus on high-volume, high-cost injectables.
Regulatory
Galderma's Relfydess Botox Rival Hits FDA Roadblock — What Practices Need to Know
The FDA issued a Complete Response Letter for RelabotulinumtoxinA, delaying Galderma's entry into the U.S. neuromodulator market.
Regulatory
Galderma Receives Complete Response Letter for Relfydess — Botox Rival Faces Regulatory Hurdle
FDA rejects Galderma's new neuromodulator formulation; shares slide on failed market-entry bid.
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.